ARCT

9.11

3.95% -0.375

시간 외 거래: 9.55 0.44 +4.83%

Arcturus Therapeutics Holdings Inc (ARCT)

개요 뉴스 가격 이력 옵션 체인 Financials 토론 예측 주식 분할

전일 마감가:

$9.485

열려 있는:

$9.12

하루 거래량:

579.45K

Relative Volume:

1.43

시가총액:

$243.54M

수익:

$157.75M

순이익/손실:

$-29.73M

주가수익비율:

-7.8534

EPS:

-1.16

순현금흐름:

$-21.00M

1주 성능:

-21.33%

1개월 성능:

-41.19%

6개월 성능:

-61.85%

1년 성능:

-70.23%

1일 변동 폭

$8.695

$9.35

1주일 범위

$8.695

$11.24

52주 변동 폭

$8.695

$45.00

Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile

명칭

Arcturus Therapeutics Holdings Inc

부문

Healthcare (1172)

산업

Biotechnology (673)

전화

(858) 900-2660

주소

10628 SCIENCE CENTER DRIVE, SAN DIEGO, CA

직원

176

트위터

@ArcturusRx

다음 수익 날짜

2024-11-07

최신 SEC 제출 서류

ARCT's Discussions on Twitter

ARCT을(를) 다른 주식과 비교

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
ARCT Arcturus Therapeutics Holdings Inc	9.11	243.54M	157.75M	-29.73M	-21.00M	-1.16
VRTX Vertex Pharmaceuticals Inc	474.62	125.40B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	573.45	65.79B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	555.11	35.18B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	235.74	32.67B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	238.51	26.46B	3.81B	-644.79M	-669.77M	-6.24

Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2025-01-28	개시	BTIG Research	Buy
2024-08-12	개시	Leerink Partners	Outperform
2023-12-13	개시	Canaccord Genuity	Buy
2023-07-24	개시	William Blair	Outperform
2023-05-11	업그레이드	H.C. Wainwright	Neutral → Buy
2022-11-14	재개	Wells Fargo	Overweight
2022-11-10	다운그레이드	Robert W. Baird	Neutral → Underperform
2022-11-03	업그레이드	Citigroup	Neutral → Buy
2022-11-02	업그레이드	Barclays	Underweight → Equal Weight
2022-08-10	다운그레이드	Raymond James	Mkt Perform → Underperform
2022-07-19	재개	Cantor Fitzgerald	Overweight
2022-05-11	업그레이드	Robert W. Baird	Underperform → Neutral
2022-04-21	다운그레이드	Citigroup	Buy → Neutral
2022-01-31	업그레이드	Raymond James	Underperform → Mkt Perform
2021-08-12	다운그레이드	Raymond James	Mkt Perform → Underperform
2021-08-11	다운그레이드	Goldman	Neutral → Sell
2021-08-10	다운그레이드	Robert W. Baird	Neutral → Underperform
2021-07-02	개시	Cantor Fitzgerald	Overweight
2021-06-25	재개	Goldman	Neutral
2021-06-21	다운그레이드	Barclays	Equal Weight → Underweight
2021-06-04	재개	Robert W. Baird	Neutral
2021-02-17	다운그레이드	B. Riley Securities	Neutral → Sell
2021-01-19	다운그레이드	B. Riley Securities	Buy → Neutral
2021-01-15	다운그레이드	B. Riley Securities	Buy → Neutral
2021-01-07	개시	Wells Fargo	Overweight
2020-12-29	다운그레이드	Barclays	Overweight → Equal Weight
2020-12-29	다운그레이드	H.C. Wainwright	Buy → Neutral
2020-12-29	다운그레이드	Raymond James	Outperform → Mkt Perform
2020-12-29	다운그레이드	Robert W. Baird	Outperform → Neutral
2020-12-23	다운그레이드	ROTH Capital	Buy → Sell
2020-12-08	재확인	B. Riley Securities	Buy
2020-12-07	재확인	B. Riley Securities	Buy
2020-10-26	개시	Barclays	Overweight
2020-10-06	개시	Citigroup	Buy
2020-08-26	개시	Piper Sandler	Overweight
2020-07-30	재개	ROTH Capital	Buy
2020-07-16	개시	Raymond James	Outperform
2020-07-13	개시	B. Riley FBR	Buy
2020-06-09	다운그레이드	WBB Securities	Buy → Hold
2020-02-11	개시	Robert W. Baird	Outperform
2020-02-07	개시	Guggenheim	Buy
2020-02-06	개시	Guggenheim	Buy
2019-04-05	개시	H.C. Wainwright	Buy
2018-09-20	업그레이드	WBB Securities	Buy → Strong Buy
2018-01-22	개시	Chardan Capital Markets	Buy

모두보기

Arcturus Therapeutics Holdings Inc 주식(ARCT)의 최신 뉴스

Mar 26, 2025

(ARCT) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Mar 26, 2025

Mar 24, 2025

Bank of New York Mellon Corp Sells 22,024 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World

Mar 24, 2025

Mar 20, 2025

Is Arcturus Therapeutics (ARCT) a Worst High-Risk High-Reward Growth Stock to Buy? - Insider Monkey

Mar 20, 2025

Benign Growth For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Underpins Stock's 26% Plummet - simplywall.st

Mar 20, 2025

Mar 18, 2025

Arcturus up 9% as phase 2 dosing begins for mRNA asset for cystic fibrosis - MSN

Mar 18, 2025

Mar 17, 2025

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $61.40 Average PT from Analysts - Defense World

Mar 13, 2025

Mar 12, 2025

Arcturus Therapeutics at Leerink’s Conference: mRNA Innovations and Strategic Plans - Investing.com UK

Mar 12, 2025

Despite Revenue Setback, Arcturus Therapeutics (ARCT) Vaccine Breakthroughs Fuel Optimism - markets.businessinsider.com

Mar 12, 2025

Mar 11, 2025

Arcturus Therapeutics (NASDAQ:ARCT) Given New $68.00 Price Target at Canaccord Genuity Group - Defense World

Mar 11, 2025

Mar 09, 2025

Analysts Have Lowered Expectations For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) After Its Latest Results - Simply Wall St

Mar 09, 2025

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Are Cutting Their Estimates: Here's What You Need To Know - Yahoo Finance

Mar 09, 2025

HC Wainwright Lowers Arcturus Therapeutics (NASDAQ:ARCT) Price Target to $60.00 - Defense World

Mar 09, 2025

Arcturus Therapeutics (NASDAQ:ARCT) Earns Overweight Rating from Cantor Fitzgerald - Defense World

Mar 09, 2025

Mar 08, 2025

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 08, 2025

Mar 07, 2025

Arcturus Therapeutics stock hits 52-week low at $14.3 By Investing.com - Investing.com Australia

Mar 07, 2025

Beyond The Numbers: 8 Analysts Discuss Arcturus Therapeutics Stock - Benzinga

Mar 07, 2025

Arcturus Therapeutics stock hits 52-week low at $14.3 - Investing.com India

Mar 07, 2025

Earnings call transcript: Arcturus Therapeutics Q4 2024 misses estimates By Investing.com - Investing.com South Africa

Mar 07, 2025

Arcturus Therapeutics Reports Q4 2024 Earnings: EPS of ($1.11) M - GuruFocus.com

Mar 07, 2025